Bright Minds Biosciences Files 6-K
Ticker: DRUG · Form: 6-K · Filed: Sep 12, 2024 · CIK: 1827401
Sentiment: neutral
Topics: filing, news-release
Related Tickers: BMBS
TL;DR
BMBS filed a 6-K, likely with a press release attached. Check for news.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on September 12, 2024, to report a news release dated the same day. The filing does not contain specific financial figures or operational updates beyond the submission of this news release as an exhibit.
Why It Matters
This filing indicates that Bright Minds Biosciences Inc. has released new information to the public, which could contain material updates for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a news release, without disclosing new financial or operational data within the filing itself.
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Filer of the report
- September 12, 2024 (date) — Date of the news release and filing
- 001-40997 (other) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report a news release dated September 12, 2024, submitted by Bright Minds Biosciences Inc.
What is the filing date of this report?
The filing date of this report is September 12, 2024.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001827401.
What is the Standard Industrial Classification (SIC) code for Bright Minds Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Bright Minds Biosciences Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What exhibits are submitted with this Form 6-K?
Exhibit 99.1, a News Release dated September 12, 2024, is submitted with this Form 6-K.
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-09-12 12:58:09
Filing Documents
- f6k20240912.htm (6-K) — 5KB
- ex991-20240912.htm (EX-99.1) — 17KB
- 0001183740-24-000073.txt ( ) — 23KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ] SUBMITTED HEREWITH Exhibits 99.1 News Release dated September 12, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: September 12, 2024